News & Resources > Publications
Publications
- Presentation:
28th Annual JP Morgan Global Healthcare Conference, San Francisco, California. January 11, 2010.
Diabetes, Obesity, and Metabolic Disease
View PDF Document - Poster Presentation:
45th Annual European Association for the Study of Diabetes Meeting, Vienna, Austria, October 1, 2009.
Impact of INT131 Besylate, a Selective PPARγ Modulator (SPPARM), on Glycemic Control in Patients with Type 2 Diabetes in a 24-Week Phase 2b Study (INT131-007)
View PDF Document - Poster Presentation:
45th Annual European Association for the Study of Diabetes Meeting, Vienna, Austria, October 1, 2009.
Chronic Cardiovascular Safety of INT131 Besylate, a Selective PPAR Modulator (SPPARM)in Rodents and Monkeys is Differentiated from TZD Full Agonists
View PDF Document - Paper:
Alykhan Motani†, Zhulun Wang†, Jennifer Weiszmann†, Lawrence R. McGee, Gary Lee, Qingxiang Liu, Jocelyn Staunton, Zexu Fang, Helen Fuentes, Michelle Lindstrom, Jinsong Liu, Donna H. T. Biermann, Juan Jaen, Nigel P. C. Walker, R. Marc Learned, Jin-Long Chen and Yang Li, "INT131: A Selective Modulator of PPARγ," J. Mol. Bio. (2009). doi:10.1016/j.jmb.2009.01025
View PDF Document - Paper:
Linda S. Higgins and Christos S. Mantzoros, "The Development of INT131 as a Selective PPARγ Modulator: Approach to a Safer Insulin Sensitizer," PPAR Research, vol. 2008, Article ID 936906, 9 pages, 2008. doi:10.1155/2008/936906.
View PDF Document - Poster Presentation:
44th EASD Annual Meeting held in Rome, Italy, September 7–11, 2008.
EASD Abstract Title: INT131, a non-TZD selective PPARγ modulator (SPPARM), does not cause toxicities typical of TZD full PPARγ agonists following 6-month high dose treatment of rats or monkeys
View PDF Document - Poster Presentation:
American Diabetes Association 68th Scientific Sessions held in San Francisco, California, June 6-10, 2008.
INT131: A Selective PPARγ Modulator (SPPARM) for Type 2 Diabetes Mellitus (T2DM)
View PDF Document
